GH Research PLC Surges on FDA Clearance for GH001
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 05 2026
0mins
Should l Buy GHRS?
GH Research PLC shares surged by 47.89% in pre-market trading, reaching a 20-day high, following positive developments regarding its drug GH001.
The significant price movement is attributed to the FDA clearance for GH001's clinical investigation, which allows for U.S. subject enrollment and marks a crucial step towards the planned Phase 3 trial in 2026. This news has heightened investor confidence in the company's ability to address treatment-resistant depression (TRD), especially given the promising results from the Phase 2b trial where GH001 demonstrated a 15.5-point reduction in MADRS scores.
As the company prepares for its upcoming Phase 3 trial, the positive market reaction reflects strong anticipation for GH001's potential impact on TRD treatment, which could lead to substantial market opportunities and revenue growth for GH Research.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy GHRS?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on GHRS
Wall Street analysts forecast GHRS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for GHRS is 28.60 USD with a low forecast of 19.00 USD and a high forecast of 35.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
6 Analyst Rating
6 Buy
0 Hold
0 Sell
Strong Buy
Current: 13.660
Low
19.00
Averages
28.60
High
35.00
Current: 13.660
Low
19.00
Averages
28.60
High
35.00
About GHRS
GH Research PLC is a clinical-stage biopharmaceutical company. The Company is engaged in offering treatment for psychiatric and neurological disorders. The Company's pipeline includes GH001, GH002 and GH003. The Company focuses on developing its 5- Methoxy-N, N-Dimethyltryptamine, (5-MeO-DMT), therapies for the treatment of patients with Treatment Resistant Depression (TRD). Its product candidate, GH001, is formulated for 5-MeO-DMT administration via an inhalation approach. With GH001, the Company has completed two Phase 1 healthy volunteer clinical trials and a Phase 1/2 clinical trial in patients with treatment-resistant depression (TRD). The GH002 is a 5-MeO-DMT product candidate formulated for administration via an injectable approach. GH002 has completed pre-clinical development to support early clinical trials. The GH003 is a 5-MeO-DMT product candidate formulated for administration via an intranasal administration approach.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
US Stocks Close Higher, S&P 500 Hits One-Week High
- Strong Market Performance: The S&P 500 index rose by 0.64%, reaching a one-week high, reflecting increased investor optimism regarding AI spending, which is driving the overall market upward.
- Energy Stocks Rally: Following President Trump's announcement of a U.S. takeover of Venezuela, energy companies saw significant gains, with Valero Energy up over 9%, indicating rising market expectations for energy resource demand.
- Increased Demand for Precious Metals: Gold prices surged over 2% and silver over 7% due to escalating geopolitical risks in South America, driving mining stocks higher and reflecting investor preference for safe-haven assets.
- Declining Bond Yields: The 10-year Treasury yield fell to 4.16%, supported by weak economic data and dovish comments from Fed officials, leading to rising bond prices and indicating changing market expectations for future interest rate policies.
See More
US Stock Indices Rise with Energy Stocks Leading Gains
- Strong Market Performance: The S&P 500 Index rose by 0.72% and the Dow Jones Industrial Average increased by 1.32%, reaching a new all-time high, reflecting strong market optimism regarding AI spending that boosted chipmakers and data storage companies.
- Energy Stock Rally: Following President Trump's announcement that the US will “run” Venezuela and require “total access” to its oil reserves, energy stocks surged, with Valero Energy leading gains at over 11%, indicating heightened market interest in energy resources.
- Rising Demand for Precious Metals: Geopolitical risks in South America have driven gold prices up by more than 3% and silver by over 7%, leading to gains in mining stocks, with Barrick Mining and Hecla Mining both rising over 4%, reflecting increased investor demand for safe-haven assets.
- Economic Data Impact: Despite the unexpected drop in the December ISM manufacturing index to 47.9, marking the steepest contraction in 14 months, dovish comments from the Philadelphia Fed President supported the stock market, suggesting continued optimism about future economic growth.
See More
Momentus Inc. Shares Surge 57% Following Fuel Tank Development Announcement
- Stock Surge: Momentus Inc. shares soared 57% to $8.98 following the announcement of an additive-manufactured fuel tank, indicating strong market confidence in its aerospace service potential.
- Flight Testing Plans: The fuel tank is scheduled for flight testing aboard the Vigoride-7 orbital service vehicle, which not only enhances the company's technological capabilities but also opens new revenue streams for future commercial launches.
- FDA Clearance: GH Research PLC shares rose 17% to $15.43 after the FDA lifted the clinical hold on its Investigational New Drug Application, marking a significant breakthrough in the company's development process that could accelerate product commercialization.
- Market Volatility: Despite a generally positive market, Zenas Biopharma Inc. shares plummeted 57% due to results from the INDIGO trial, reflecting the high-risk nature of the biopharmaceutical sector, necessitating cautious investment evaluations.
See More
US Stocks Rise as Energy Shares Surge on Venezuela Situation
- Market Gains: The S&P 500 Index rose by 0.54%, the Dow Jones Industrial Average increased by 0.99%, and the Nasdaq 100 Index climbed by 0.78%, reflecting strong market optimism regarding AI spending that is driving overall stock performance higher.
- Energy Stocks Surge: Following President Trump's announcement of a U.S. takeover of Venezuela, energy companies saw significant stock increases, with Valero Energy up over 9%, Halliburton and SLB rising more than 7%, indicating strong market demand for oil and gas resources.
- Rising Precious Metals Demand: Escalating geopolitical risks in South America led to gold prices increasing by over 2% and silver by more than 5%, boosting mining stocks like Barrick Mining and Newmont Mining by over 2%, reflecting investor preference for safe-haven assets.
- Fed Policy Expectations: Dovish comments from the Philadelphia Fed President supported stock market gains, with expectations of potential interest rate cuts in the future enhancing confidence in economic growth, further propelling positive stock market performance.
See More
Altimmune Inc Receives FDA Breakthrough Therapy Designation for Pemvidutide, Shares Surge 23.6%
- FDA Certification Impact: Altimmune Inc's Pemvidutide received FDA Breakthrough Therapy Designation, leading to a 23.6% surge in shares to $4.34 on Monday, indicating strong market confidence in its potential efficacy and possibly accelerating its path to market.
- Clinical Progress: GH Research PLC's GH001 lifted from FDA clinical hold saw shares rise 33.8% to $17.72, reflecting significant advancements in drug development that are expected to enhance its competitive position in the market.
- Executive Change: Rayonier Advanced Materials Inc appointed Scott M. Sutton as the new CEO, resulting in a 14.1% increase in shares to $6.68, suggesting that this leadership change could bring new strategic directions and growth opportunities for the company.
- Market Rebound: The overall market showed strong performance with the S&P 500 index rising, reflecting investor optimism about economic recovery, which may drive more capital inflows into the stock market.
See More
GH Research (GHRS) FDA Lifts Clinical Hold on GH001, Shares Surge 42%
- Clinical Hold Lifted: GH Research PLC announced that the FDA has lifted the clinical hold on its Investigational New Drug Application for GH001, enabling U.S. subject enrollment and advancing the company's development alignment across major jurisdictions.
- Global Program Initiation Expected: CEO Velichka Valcheva stated that the company anticipates initiating its global pivotal program in 2026, which will not only accelerate product development but also enhance the company's position in the competitive biopharmaceutical market.
- Positive Stock Reaction: In pre-market trading on NasdaqGM, GH Research shares surged 42% to $18.81, reflecting strong market optimism regarding the company's future prospects following the FDA's announcement.
- Follow-up Meeting with FDA: The company looks forward to meeting with the FDA to align on the design for the pivotal Phase 3 program, which will lay the groundwork for future clinical trials and potentially expedite the product's market entry.
See More
US Stocks Close Higher, S&P 500 Hits One-Week High
- Strong Market Performance: The S&P 500 index rose by 0.64%, reaching a one-week high, reflecting increased investor optimism regarding AI spending, which is driving the overall market upward.
- Energy Stocks Rally: Following President Trump's announcement of a U.S. takeover of Venezuela, energy companies saw significant gains, with Valero Energy up over 9%, indicating rising market expectations for energy resource demand.
- Increased Demand for Precious Metals: Gold prices surged over 2% and silver over 7% due to escalating geopolitical risks in South America, driving mining stocks higher and reflecting investor preference for safe-haven assets.
- Declining Bond Yields: The 10-year Treasury yield fell to 4.16%, supported by weak economic data and dovish comments from Fed officials, leading to rising bond prices and indicating changing market expectations for future interest rate policies.
See More
US Stock Indices Rise with Energy Stocks Leading Gains
- Strong Market Performance: The S&P 500 Index rose by 0.72% and the Dow Jones Industrial Average increased by 1.32%, reaching a new all-time high, reflecting strong market optimism regarding AI spending that boosted chipmakers and data storage companies.
- Energy Stock Rally: Following President Trump's announcement that the US will “run” Venezuela and require “total access” to its oil reserves, energy stocks surged, with Valero Energy leading gains at over 11%, indicating heightened market interest in energy resources.
- Rising Demand for Precious Metals: Geopolitical risks in South America have driven gold prices up by more than 3% and silver by over 7%, leading to gains in mining stocks, with Barrick Mining and Hecla Mining both rising over 4%, reflecting increased investor demand for safe-haven assets.
- Economic Data Impact: Despite the unexpected drop in the December ISM manufacturing index to 47.9, marking the steepest contraction in 14 months, dovish comments from the Philadelphia Fed President supported the stock market, suggesting continued optimism about future economic growth.
See More
Momentus Inc. Shares Surge 57% Following Fuel Tank Development Announcement
- Stock Surge: Momentus Inc. shares soared 57% to $8.98 following the announcement of an additive-manufactured fuel tank, indicating strong market confidence in its aerospace service potential.
- Flight Testing Plans: The fuel tank is scheduled for flight testing aboard the Vigoride-7 orbital service vehicle, which not only enhances the company's technological capabilities but also opens new revenue streams for future commercial launches.
- FDA Clearance: GH Research PLC shares rose 17% to $15.43 after the FDA lifted the clinical hold on its Investigational New Drug Application, marking a significant breakthrough in the company's development process that could accelerate product commercialization.
- Market Volatility: Despite a generally positive market, Zenas Biopharma Inc. shares plummeted 57% due to results from the INDIGO trial, reflecting the high-risk nature of the biopharmaceutical sector, necessitating cautious investment evaluations.
See More
US Stocks Rise as Energy Shares Surge on Venezuela Situation
- Market Gains: The S&P 500 Index rose by 0.54%, the Dow Jones Industrial Average increased by 0.99%, and the Nasdaq 100 Index climbed by 0.78%, reflecting strong market optimism regarding AI spending that is driving overall stock performance higher.
- Energy Stocks Surge: Following President Trump's announcement of a U.S. takeover of Venezuela, energy companies saw significant stock increases, with Valero Energy up over 9%, Halliburton and SLB rising more than 7%, indicating strong market demand for oil and gas resources.
- Rising Precious Metals Demand: Escalating geopolitical risks in South America led to gold prices increasing by over 2% and silver by more than 5%, boosting mining stocks like Barrick Mining and Newmont Mining by over 2%, reflecting investor preference for safe-haven assets.
- Fed Policy Expectations: Dovish comments from the Philadelphia Fed President supported stock market gains, with expectations of potential interest rate cuts in the future enhancing confidence in economic growth, further propelling positive stock market performance.
See More
Altimmune Inc Receives FDA Breakthrough Therapy Designation for Pemvidutide, Shares Surge 23.6%
- FDA Certification Impact: Altimmune Inc's Pemvidutide received FDA Breakthrough Therapy Designation, leading to a 23.6% surge in shares to $4.34 on Monday, indicating strong market confidence in its potential efficacy and possibly accelerating its path to market.
- Clinical Progress: GH Research PLC's GH001 lifted from FDA clinical hold saw shares rise 33.8% to $17.72, reflecting significant advancements in drug development that are expected to enhance its competitive position in the market.
- Executive Change: Rayonier Advanced Materials Inc appointed Scott M. Sutton as the new CEO, resulting in a 14.1% increase in shares to $6.68, suggesting that this leadership change could bring new strategic directions and growth opportunities for the company.
- Market Rebound: The overall market showed strong performance with the S&P 500 index rising, reflecting investor optimism about economic recovery, which may drive more capital inflows into the stock market.
See More
GH Research (GHRS) FDA Lifts Clinical Hold on GH001, Shares Surge 42%
- Clinical Hold Lifted: GH Research PLC announced that the FDA has lifted the clinical hold on its Investigational New Drug Application for GH001, enabling U.S. subject enrollment and advancing the company's development alignment across major jurisdictions.
- Global Program Initiation Expected: CEO Velichka Valcheva stated that the company anticipates initiating its global pivotal program in 2026, which will not only accelerate product development but also enhance the company's position in the competitive biopharmaceutical market.
- Positive Stock Reaction: In pre-market trading on NasdaqGM, GH Research shares surged 42% to $18.81, reflecting strong market optimism regarding the company's future prospects following the FDA's announcement.
- Follow-up Meeting with FDA: The company looks forward to meeting with the FDA to align on the design for the pivotal Phase 3 program, which will lay the groundwork for future clinical trials and potentially expedite the product's market entry.
See More
